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Abstract
Background: There is urgent need for effective HIV prevention methods that women can initiate. The CAPRISA 004
trial showed that a tenofovir-based vaginal microbicide had significant impact on HIV incidence among women.
This study uses the trial findings to estimate the population-level impact of the gel on HIV and HSV-2 transmission,
and price thresholds at which widespread product introduction would be as cost-effective as male circumcision in
urban South Africa.
Methods: The estimated ‘per sex-act’ HIV and HSV-2 efficacies were imputed from CAPRISA 004. A dynamic HIV/STI
transmission model, parameterised and fitted to Gauteng (HIV prevalence of 16.9% in 2008), South Africa, was used
to estimate the impact of gel use over 15 years. Uptake was assumed to increase linearly to 30% over 10 years, with
gel use in 72% of sex-acts. Full economic programme and averted HIV treatment costs were modelled. Cost per
DALY averted is estimated and a microbicide price that equalises its cost-effectiveness to that of male circumcision
is estimated.
Results: Using plausible assumptions about product introduction, we predict that tenofovir gel use could lead to a
12.5% and 4.9% reduction in HIV and HSV-2 incidence respectively, by year 15. Microbicide introduction is predicted
to be highly cost-effective (under $300 per DALY averted), though the dose price would need to be just $0.12 to
be equally cost-effective as male circumcision. A single dose or highly effective (83% HIV efficacy per sex-act)
regimen would allow for more realistic threshold prices ($0.25 and $0.33 per dose, respectively).
Conclusions: These findings show that an effective coitally-dependent microbicide could reduce HIV incidence by
12.5% in this setting, if current condom use is maintained. For microbicides to be in the range of the most
cost-effective HIV prevention interventions, product costs will need to decrease substantially.
Keywords: HIV, Modelling, Cost-effectiveness, Microbicides, South Africa, Introduction of new technologies,
Economic analysis, Tenofovir, ARV-based prevention, Pre-exposure prophylaxis (PreP)
Background
There is an urgent need for effective HIV prevention
methods that can be initiated by women. After a decade
of little progress in HIV prevention interventions, recent
trials have shown that antiretrovirals can be used to
prevent HIV incidence and infectivity [1-4]. In 2010, the
CAPRISA 004 trial in Kwazulu Natal, South Africa,
showed that the incidence of HIV infection among women
randomised to using a topical gel containing 1% of the
antiretroviral tenofovir before and after sex, was reduced
by 39% (95% CI 6-60%). In addition, women’s risk of ac-
quiring herpes simplex virus type-2 (HSV-2) was reduced
by 51% (95% CI 22-70%) [5,6]. This finding was ground-
breaking, being the first clinical trial to show a statistically
significant impact of a microbicide product on HIV inci-
dence, and providing a proof of concept that a topically
applied antiretroviral microbicide can reduce women’s risk
of HIV acquisition [7]. The FACTS 001 trial is now
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seeking to confirm the CAPRISA results, and assess the
generalizability of the findings across different settings [8].
Plans are underway to prepare for the possible introduc-
tion and manufacture of tenofovir gel. Once this trial is
completed, its data will be combined with the CAPRISA
004 results and presented together for regulatory approval.
This study aims to inform this process and the field of
HIV more broadly.
Evidence from FACTS 001 and this cost-effectiveness
analysis will be evaluated in the context of VOICE trial
results that showed that daily administration of the same
product and oral tenofovir did not achieve a significant
reduction in HIV incidence due to adherence issues [9].
It appears that compliance to a daily regimen of gels or
pills is not a viable option for African women in particular
for younger women. However, given the positive findings
from CAPRISA, there is still hope that a coitally-specific
product may provide a feasible strategy for women who
are unable to protect themselves with the current range of
options available.
In parallel to clinical research, it is important to explore
the potential population-level impact that tenofovir gel
introduction could have on HIV incidence in different epi-
demic settings, and identify key factors that may influence
the impact and cost-effectiveness of future product intro-
duction. Towards this end, this paper uses modelling and
the CAPRISA trial results to estimate the gel’s likely level
of protection against HIV and HSV-2 during each sex-act
(here termed the ‘imputed efficacy’), and the potential
population-level impact on HIV and HSV-2 of gradual
product introduction in an urban setting with high HIV
prevalence and incidence in South Africa. Using South
Africa specific unit cost data, the full cost of introducing
microbicides into the public health sector is modelled first.
Secondly, threshold product prices are identified at which
point the costs per HIV infection averted are equal to
that of voluntary medical male circumcision (VMMC)
(~$1000 per infection averted) [10], an intervention widely
accepted as cost-effective and efficient. A range of scenar-
ios are used to explore the effects of various assumptions
on this threshold.
Methods
Setting
For the modelling analysis, we considered product intro-
duction in Gauteng Province, a highly urbanised prov-
ince of South Africa with a population of reproductive
age (aged 15 – 45 years) of 5.7 million. HIV prevalence
among those aged 15–49 was 16.9% in 2008 [11], with a
higher prevalence among females (21.1%) than males
(11.2%) documented in 2005 [12]. Commercial sex work
is an important driver of the HIV epidemic in Gauteng
[13], with behavioural surveys suggesting that 6.4% of
female family-planning clinic attendees had transactional
sex in the last four weeks [14].
Microbicide introduction scenarios modelled
A review of evidence and discussions with key stake-
holders in South Africa and internationally were used to
inform the microbicide introduction strategies considered
in this paper [15]. As described in more detail below, we
considered the provision of a microbicide through the
public health system, assuming that mass media cam-
paigns are used to increase awareness of the product avail-
ability; health providers are trained to provide the product,
and they then routinely provide HIV testing, and counsel
HIV negative clients about product use and the import-
ance of adherence and repeated HIV testing [15].
As in the CAPRISA 004 trial, we consider a coitally-
dependent gel, with two doses used per sex-act. We as-
sumed that the mean consistency of gel use is the same
as in the CAPRISA 004 trial (two doses used in 72% of
sex-acts)a, irrespective of the type of partnership. In
addition, a more pessimistic scenario of 50% gel use was
considered.
In the CAPRISA trial, reported condom use increased
from 79% in the first six months to 84% in the last six
months (P < 0.001) [5].b In this analysis we considered
two potential scenarios. Firstly, we assumed that condom
use is unaffected by gel use and HIV testing (and remains
at the levels detailed in Additional file 1: Table S2 of the
appendix). Secondly, we consider more pessimistic as-
sumptions that there is a 5% or 10% absolute reduction
in condom use among microbicide users.
In this analysis, we consider the impact on HIV and
HSV-2 incidence of population-level gel distribution
over 15 years, starting in January 2013. We assume that,
following regulatory approval, tenofovir is made available
to HIV-negative sexually active women attending public
health facilities, alongside regular HIV testing.
Based on a review of the evidence on the rate of uptake
of condoms and other new health technologies [16], we
assume that for the first 10 years the proportion of HIV-
negative women using the gel increases linearly, plateauing
at 30%, half the rate at which urban sexually active women
are currently accessing modern contraceptives in Gauteng
[17], for the remaining five years. A more optimistic
scenario of 60% uptake after 10 years was also explored.
Imputed efficacy calculations
The CAPRISA 004 trial results represent an estimate of
the average protection achieved across all users in the
active arm of the trial, including those who used the gel
consistently or intermittently, and those who did not use
it at all [18]. As a result, for the modelling we need to
impute the level of protection provided by the product
against HIV and HSV-2 in each sex-act between
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a susceptible woman and an infected partner (that is,
how much it reduces the probability of transmission
during each act of intercourse). This was estimated by
dividing the trial effectiveness by the percentage of all
reported sex-acts in which gel was used [5,6,18,19].
Details of this calculation and the assumptions made are
provided in the online Additional file 1. The imputed
efficacy estimates were then used in the dynamic impact
model. We also investigated the contribution of the gel’s
HSV-2 efficacy on HIV transmission and vice versa.
Description of the model structure
The HIV and HSV-2 impact projections were obtained
using a population-level deterministic compartmental
HIV/STI transmission model, adapted to enable the im-
pact of the gradual introduction of a microbicide to be
explored [20]. The mathematics underlying the dynamic
transmission model are described in Vickerman et al.
[21], and in the online Additional file. In brief, the model
divides the heterosexual population into subgroups, with
stratifications by sex, level of sexual activity and HIV/
STI infection status. Using data on the probabilities of
disease transmission and progression from the epidemio-
logical literature, established mathematical techniques are
used to estimate how HIV spreads between the different
subgroups over time [22,23]. The transmission of HSV-2,
syphilis and gonorrhoea/chlamydia are simulated, in-
cluding the facilitating effect of these STIs on HIV
transmission, and the effect of HIV on increasing the
rate of HSV-2 symptomatic recurrences and HSV-2 in-
fectivity (during both asymptomatic and symptomatic
stages of infection) [24]. The model also incorporates
the higher HIV infectivity associated with primary and
late-stage HIV infection (in the absence of HIV treat-
ment), and the effect of ongoing STI treatment and
antiretroviral therapy (ART) in the population on levels
of HIV infectivity [25], of which more detail can be found
in the online supplement.
Fitting the model to the setting
The model was parameterised and fitted using behavioural
and epidemiological data from Gauteng, and complemen-
tary data from South Africa (Figures 1a, b, c and online
Additional file 1). The approach used incorporates the un-
certainty inherent in key model parameters by running the
model over a large number (almost 4 billion) of permuta-
tions of model inputs. These are obtained by randomly
sampling from the uncertainty ranges for each model
input parameter (Additional file 1: Tables S2-S4) [21]. As
is standard in HIV modelling, the model is seeded with a
few HIV infected individuals (0.5% in the general popula-
tion and 5% among female sex workers) in 1980 and run
until 2028 (to model 15 years from 2013). A ‘fit’ is defined
as a model simulation that lies within the 95% confidence
intervals (CIs) of setting-specific HIV and STI prevalence
data. The model was fitted to HIV data from three
national surveys, using disaggregated male and female
prevalence values when available (for 2002, 2005) and a
combined prevalence for 2008 (five HIV prevalence data
points in total for the general population) [11,12,26]; and
also to HIV prevalence data among female sex workers
(FSWs) (1997) and their clients (2000). Additionally, the
model was fitted to syphilis and gonorrhoea/chlamydia
prevalence data from FSWs (1997) [13,27]. HSV-2 data
from the CAPRISA trial [5], adjusting for HIV status [11],
was used as a proxy for the general population HSV-2
prevalence. Each combination of input values that fit to
the observed prevalence data is used in the final impact
projections, with the best-fit identified through least
chi-squared error.
Methods used for the economic evaluation of gel
introduction
Full programme costs are offset by the HIV care and
treatment costs saved resulting from averting HIV infec-
tions to estimate incremental costs. We present the in-
cremental cost-effectiveness ratios (ICER) in terms of
dollar per disability adjusted life year (DALY) averted.
Interventions with ICERs of less than per capita GDP
($7160 for South Africa) per averted DALY are consid-
ered highly cost-effective and worth introducing [28],
but require either additional resources or re-allocation
of resources. We also identify the threshold microbicide
prices where the cost per HIV infection averted is equal
to the cost per HIV infection averted of VMMC in
South Africa to better understand under which conditions
microbicide introduction would be as cost-effective as
VMMC.
The economic costs of a comprehensive microbicide
distribution programme were estimated from the pro-
vider’s perspective using an ingredients-based approach
and unit cost from the South African public sector. This
includes HIV testing [29], facility based provider training
[30] and health facility costs, including staff, for the initi-
ation visit and subsequent adherence counselling and gel
distribution visits [31-33], 10% product wastage [34],
and periodic mass media campaigns [35]. This analysis
assumes general population HIV testing is in place and
the initial screening costs are not included.
All costs are presented in 2012 US dollars ($). All fu-
ture costs and effects are discounted to present values,
using a 3% discount rate. The current price of a single
dose of tenofovir gel as produced for the FACTS 001
trial is $1.60 [36]. The predicted price of a packaged
and labelled gel at low production scale (10 million
doses) is $0.56, while this could be as low as $0.17 if
distributed at large scale with a tube of gel and fillable
paper applicators [36].
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For the 52% of those in need of ART who are receiving
ART [37], 2012 annual treatment costs are used ($562
for first line ART and $1094 for second line) [38], with
an lifetime cost of $14,310 assuming a near normal life
expectancy due to ART [39]. For those without ART
access, discounted lifetime HIV care costs of $3,080 are in-
cluded [33]. This gives a discounted weighted average HIV
care and ART costs averted of $8,920 per HIV infection
averted. Though HSV-2 treatment with acyclovir is first
line therapy for genital ulcer disease, these averted costs
have not been included which will render the analysis on
the conservative side.
An economic evaluation in terms of cost per DALY
averted is estimated at a range of product prices with
the central price being $0.25 (including $1.60, $0.56, and
$0.17). Standard DALY estimates are used [40], with HIV
disability weights drawn from the 2010 Global Burden of
Disease study as presented in Ortblad [41]. Details of
the economic evaluation methods are presented in the
Additional file 1: Table S5. To approximate the price
thresholds where microbicide introduction is roughly as
cost effective as VMMC scale up ($1087 and $1096 per
infection averted to scale up to 60% and 80%, respect-
ively, from the current rate of 45%). To err on the con-
servative side, we use a $1,000 per infection averted
threshold. Threshold prices are estimated under a range
of assumptions (number of annual HIV tests and clinic
visits (two to six times per year for both) and dosing
(one to two doses per sex-act), and epidemiological sce-
narios). A sensitivity analysis is undertaken to understand
the possible impact on the threshold price of: the prices
of ART (−25%, -50%) and all other inputs (+/− 25%),
discount rate (0%, 6%c), and treatment access rates (80%).
Results
Imputed efficacy and HIV incidence projections
The imputed efficacy calculations suggest that tenofo-
vir gel reduced the per sex-act probability of HIV
Figure 1 Model-projected HIV prevalence and incidence trends over time and data used to fit model*. a: HIV prevalence trends among
general population males and females in 2002 and 2005. b: HIV prevalence trends among the general population and among female sex workers
in 2008. c: HIV incidence trends among general population males and females. *The points with error bars for males and females in 2002 and
2005 represent the mean and 95% confidence intervals derived from data [12,26]. The dotted line represents the model-projected female HIV
prevalence while the solid line represents the model-projected male HIV prevalence. The shaded areas represent the range of prevalence estimates
spanned by all model fits.
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acquisition by 54% (95% CrI 8-83%) and the per sex-act
probability of HSV-2 acquisition by 71% (95% CrI 30-
97%). Using these as inputs in the population-level mod-
elling, the projected impact on HIV incidence is shown
in Figure 2.
Table 1 presents the projected impact of microbicide
introduction under a number of scenarios. In the main
intervention scenario with mean efficacies (30% uptake
achieved over 10 years, gel used in 72% of sex-acts and
no reduction in condom use), we predict that the gel
could lead to a 12.5% (95%CrI 11.5-12.7%) relative reduc-
tion in HIV incidence and a 4.9% (95%CrI 4.7%-5.5%) rela-
tive reduction in HSV-2 incidence by year 15. This is a
reduction in HIV incidence in the whole population from
0.56 (95%CrI 0.48-0.72) per 100 person-years to 0.49 (95%
CrI 0.42-0.64) per 100 person-years, and a reduction in
HSV-2 incidence from 7.4 (95%CrI 6.4-7.5) per 100
person-years to 7.1 (95%CrI 6.0-7.1) per 100 person years.
These reductions in incidence translate into averting
970 (95%CrI 864–1,019) HIV infections and 1,471 (95%
CrI 1,336-1,543) HSV-2 infections per 100,000 population
(Table 1) over 15 years. In this main scenario, one HIV in-
fection and one HSV-2 infection is averted for every 1,317
(95%CrI 1,266-1,481) and 868 (95%CrI 831–977) microbi-
cide protected sex-acts, respectively.
The impact projections are dependent upon the as-
sumptions made regarding gel’s efficacy, consistency and
uptake, and the degree to which condom use may or may
not be affected by gel introduction. For example, if the gel
is used in 50% rather than 72% of sex-acts, then the
number of HIV infections averted is reduced by 30% in
relative terms.
Figure 2 shows how the HIV impact is affected by a
number of modelling assumptions; the dark bars represent
the main intervention scenario. Gel efficacy is very import-
ant, with a very highly efficacious gel potentially reducing
HIV incidence by 19.0%, while a gel with poor efficacy
provides little population protection. Higher levels of
uptake can have an important impact with a doubling of
uptake resulting in a doubling of impact. There is also a 25%
relative reduction in impact if condoms are used in 5% fewer
sex-acts but uptake and gel use is maintained (Figure 2).
Interestingly the model projections suggest the HSV-2
efficacy of the gel contributes little to HIV-impact. Even
without any HSV-efficacy, the relative reduction in HIV
incidence is still projected to be 12.0% after 15 years for
the main intervention scenario compared to 12.5% if the
gel is 71% HSV-2-efficacious. However, the HIV efficacy
has an important influence on HSV-2 incidence: the
relative reduction in HSV-2 incidence is projected as
4.9% with 54% HIV efficacy versus 3.5% if the gel has no
HIV efficacy.
Microbicide cost effectiveness and threshold prices
Table 2 presents the cost-effectiveness of microbicide
introduction. For the main intervention scenario (30%
uptake, 72% gel use, 54% HIV efficacy) with two gels per
sex-act, three HIV tests and collection visits per year
(after the initiation visit), the cost per DALY averted is
$297 at the price of $0.25 per dose. At current trial
Figure 2 Projected population-level HIV impact in Gauteng for different assumptions about gel efficacy, uptake and use, and its
influence on condom use**. **Main shaded bars show best-fit model projections and error bars indicate range spanned by 95% of all model fits
(2.5% to 97.5% percentile range or 95% credibility interval), with the dark bars illustrating the main scenario (54% HIV efficacy and 71% HSV-2
efficacy, gel uptake reaching 30% by year 10, gel used in 72% of sex-acts, and no reduction in condom use).
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Table 1 Projected impact from microbicide intervention*
Mean efficacies Low efficacies High efficacies
(54% HIV efficacy and 71% HSV-2
efficacy)
(8% HIV efficacy and 30% HSV-2
efficacy)
(83% HIV efficacy and 97% HSV-2
efficacy)
Trial consistency
of gel use (72%)
Reduced consistency
of gel use (used in
50% of sex-acts)
Trial consistency
of gel use (72%)
Reduced consistency
of gel use (used in
50% of sex-acts)
Trial consistency
of gel use (72%)
Reduced consistency
of gel use (used in
50% of sex-acts)
HIV impact projections*:
Percentage reduction
in population HIV
incidence by year 15
12.5% 8.7% 2.0% 1.4% 19.0% 13.3%
(11.5-12.7%) (8–8.8%) (1.8-2.0%) (1.3-1.4%) (17.6-19.3%) (12.3-13.5%)
Cumulative number
of HIV infections
averted over 15 years
55,366 38,382 8,661 6,011 85,026 58,900
(49,309-58,173) (34,132-40,297) (7,708-9,255) (5,348-6,422) (75,845-89,447) (52,447-61,890)
Cumulative number
of HIV infections
averted per 100,000
population
970 672 152 105 1,489 1,031
(864-1,019) (598-706) (132-162) (94-112) (1,328-1,560) (918-1,084)
Number of sex-acts
protected by gel per
HIV infection averted
1,317 1,896 8,372 12,060 861 1,239
(1,266-1,481) (1,853-2,133) (8,176-9,257) (11,779-13,338) (839–966) (1,209-1,392)
HSV-2 impact projections*:
Percentage reduction
in population HSV-2
incidence in year 15
4.9% 3.4% 1.6% 1.1% 7.0% 4.8%
(4.7-5.5%) (3.2-3.7%) (1.5-1.8%) (1.0-1.2%) (6.8-7.9%) (4.6-5.4%)
Cumulative number
of HSV-2 infections
averted over 15 years
83,997
(76,312-88,153)
57,343
(52,139-60,191)
27,181
(24,537-28,617)
18,723
(16,930-19,711)
121,846
(110,559-127,721)
82,662
(75,047-86,655)
Cumulative number
of HSV-2 infections
averted per 100,000
population
1,471 1,004 476 327 2,133 1,447
(1,336-1,543) (913-1,054) (430-501) (296-345) (1,936-2,236) (1,314-1,518)
Number of sex-acts
protected by gel per
HSV-2 infection
averted
868 1,269 2,668 3,872 601 883
(831-977) (1,213-1,428) (2,566-2,994) (3,721-4,346) (575-677) (845-994)
*Assuming gel only used by HIV-negative women, and levels of condom use are maintained after microbicide introduction.
Table 2 Cost-effectiveness and threshold prices under varying programmatic assumptions (2012 US$)*
Cost per DALY averted at
$0.25 per dose
Microbicide threshold prices
where $/infection averted
(IA) = VMMC (~$1000/IA)
2 doses per sex-act 1 dose per sex-act 2 gels per sex-act
Baseline programme: 3 annual HIV tests, 3 gel collection visits $297 $0.12
Variations to distribution services
HIV tests per year 2 $190 −36% -$29 −137% $0.19 49%
4 $405 36% $186 137% $0.06 −49%
6 $619 108% $401 411% Cannot be achieved
Adherence counselling and gel collection visits 2 $272 −9% $53 −32% $0.14 12%
6 $374 26% $155 97% $0.08 −35%
Integrated adherence counselling and gel collection into HIV testing (3) $221 −26% $2 −97% $0.17 35%
*Assuming 30% uptake after 10 years and trial consistency of gel use and mean imputed efficacy estimates, 10% product wastage during distribution, and a 3%
discount rate on costs and effects.
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product costs of $1.60, the cost per DALY averted would
be $2,660. At the lowest production cost, $0.17 using
cardboard applicators and large scale production, the
cost per DALY averted would be as low as $157. This
variation emphasises the large contribution of the prod-
uct in the total programme costs, ranging from 42% at
the lowest price ($0.17) up to 87% at the highest price
($1.60). At $0.25, the product accounted for 51% of total
programme costs, while HIV counselling and testing
accounted for 38% of costs: each extra HIV test would
increase the cost-effectiveness ratio by 36%. The health
facility costs of visits for adherence counselling and gel
collection are relatively low, contributing only 9% to
programme costs: changes in collection frequency pro-
vide little savings or extra costs. However, a more inte-
grated approach, with adherence counselling and gel
distribution during the HIV testing visit, may be more
attractive to clients and is more efficient, at $221 per
DALY averted. For microbicide introduction to be
equally cost-effective as VMMC, product costs would
need to drop below our lowest estimated production
cost, to $0.12 for the base scenario. By integrating gel
collection and HIV testing, or by reducing the HIV tests
to two per year, the cost threshold would just reach or
surpass our lowest projected product cost.
We also model the cost-effectiveness and threshold
prices for variations to gel uptake, use consistency, and
HIV efficacy, linked with the different impact scenarios
(Table 3). A five percentage point absolute decrease in
the percentage of sex-acts in which a condom is used
would increase the cost to $548 per DALY averted (i.e.
worsen the cost-effectiveness), and a reduction in con-
dom use of 10 percentage points would generate a cost
of $1,219 per DALY averted. A more efficacious gel
could cost as much as $0.33 per dose to be equally cost-
effective as VMMC, and at $0.25 would generate an cost
saving, indicated by the negative cost per DALY averted
(−$14). Consistency of gel use (adherence) is also im-
portant, where only using gel in half the sex-acts reduces
effectiveness by more than the reduction in costs, with
cost of $468 per DALY averted. This worsening is attrib-
utable to maintaining the annual fixed costs per facility
and woman, while reducing gel use, and emphasises how
important user behaviour will be in the products’ ultim-
ate cost-effectiveness. Uptake, however, has a relatively
small impact on the break-even point: doubling uptake
just increases the threshold price by 5%, with both the
fixed cost of reaching women and their gel use being
reduced.
A sensitivity analysis of key cost assumptions is presented
in the bottom half of Table 3.
If a single dose regimen were found, the price could be
as high as $0.25, in line with expectations of production
costs at scale. Though cost-effectiveness analyses have
Table 3 Cost-effectiveness and threshold gel prices under variations to introduction scenario assumptions and
sensitivity analysis [2012 USD]
Variations to introduction scenario
Reduction in
condom use
Coverage Consistency
of gel use
HIV efficacy $/DALY averted % change Threshold price % change
Baseline 0% 30% 72% 54% $297 $0.12
5% 30% 72% 54% $586 97% $0.03 −74%
10% 30% 72% 54% $1,219 310% cannot be achieved
0% 60% 72% 54% $285 −4% $0.13 5%
0% 60% 50% 54% $468 58% $0.03 −78%
0% 30% 72% 83% -$14 −105% $0.33 166%
Cost sensitivity analysis
1 dose per sex-act $78 −74% $0.25 100%
Discount rate 0% -$243 −182% $0.43 244%
Discount rate 6% $525 77% cannot be achieved
ART costs 10% lower $344 16% $0.10 −21%
ART costs 25% lower $413 39% $0.06 −53%
All other input costs 25% higher $402 35% $0.06 −48%
All other input costs 25% lower $193 −35% $0.18 48%
Input +25%, ART-10% $448 51% $0.04 −69%
Input +25%, ART-25% $518 74% -$0.00 −100%
ART coverage 80% $163 −45% $0.24 90%
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traditionally assumed an international discount rate of 3%,
more recent analyses have started using local discount
rates to account for local time preferences which then
better represent local decision making. The South African
official discount rate in 2012 was 5.5%. A 6% discount rate
has a very large impact on the cost-effectiveness: $525 per
DALY averted at 6% versus cost saving when discounting
is removed in the costs. As the cost of ART provision has
decreased dramatically over the past decade, we also
explore the trade-off between treatment and prevention
for lower ART provision costs. If ART costs were to drop
by either 10% or 25%, the cost-effectiveness of providing
microbicides would worsen, increasing to $413 per DALY
averted. To account for variations in programme costs we
explored changes to all other input prices by +/− 25%,
which would change cost-effectiveness ratio by −/+ 35%,
respectively. In the most conservative case, where
programme costs were increased by 25% and ART costs
decreased by 25%, the cost DALY averted is estimated at
$518. If ART coverage were expanded from 52% to 80%,
in line with the 2016 national target [37], then the
threshold price of microbicides could be $0.24. Though
under most circumstances the explored microbicides
are unlikely to be as cost-effective as VMMC, they would
however reach a complementary target group (women) to
which VMMC can never provide direct protection.
Discussion and conclusions
We have used detailed mathematical and economic
modelling to estimate the impact and break-even price
of tenofovir gel as introduced and distributed in urban
South Africa. Our findings suggest that, for the main
scenario considered, gel introduction could be an import-
ant addition to existing HIV prevention efforts, leading to
a 12.5% (95%CrI 11.5-12.7%) relative reduction in HIV
incidence and a 4.9% (95%CrI 4.7-5.5%) relative reduction
in HSV-2 incidence over 15 years. The impact on HSV-2
is less than the impact on HIV, despite the higher efficacy
against HSV-2, due to higher risk of HSV-2-infection for
women.
Our findings suggest that the introduction of an
effective gel could be cost saving at reasonable gel
prices, in particular as ART access is expanded, and highly
cost-effective even at current gel prices.
Indeed, using plausible assumptions about the full costs
of programme delivery, we predict that the introduction of
an HIV efficacious gel would be highly cost-effective ($297
per DALY averted) at a price of $0.25, which is within the
cost range ($0.17-$0.27) at large scale production of 100
million applicators [36]. In our model this scale of distri-
bution is achieved from year 9 onwards. If South Africa
reaches its target of 80% on ART or a single dose regimen
is found to be effective, we can expect microbicides to
be around the same cost per HIV infection averted as
VMMC.
Even at current FACTS 001 trial production prices
($1.60) [36], the incremental cost per DALY averted would
be around $2,660, which is well below the commonly
applied cost-effectiveness threshold of 1*GDP ($7,610 for
South Africa) [42].
Using the trial estimates of 72% adherence, we impute
that the HIV and HSV-2 per sex-act efficacies of tenofovir
gel are 54% (95% CrI 8-83%) and 71% (95%CrI 30-97%),
respectively. Although these estimates are based upon the
trial measures of gel adherence reporting, we considered
that these are reasonably reliable, as gel applicator returns
were found to correlate well with vaginal tenofovir con-
centration measured in a pharmacokinetics sub-study
[43]. We are also reassured about the validity of our im-
puted efficacy estimates because a secondary analyses of
the effectiveness among ‘high adherers’ in the trial (i.e.
women who used both doses of the gel in over 80% of sex-
acts) found that the risk of HIV acquisition in this popu-
lation was reduced by 54% (95%CI 4-80%) [5]. However,
the wide bounds on the imputed efficacy estimates of
tenofovir gel, due to the wide confidence intervals on
the trial effectiveness estimates, lead to a wide range of
population-level impact estimates predicted by the model.
This analysis builds upon our previous modelling of the
potential impact of microbicide introduction in different
settings [44-48], as well as the work by Williams et al.
[48], Verguet et al. [39] and Walensky et al. [49-51]. Add-
itional strengths here include that the dynamic model is
carefully parameterised and rigorously fitted to a specific
setting over multiple time points, including fitting to HIV
and STI infection status by sex, as well as incorporating
the HSV-2-efficacy of tenofovir found in CAPRISA 004
and the related bi-directional interaction between HSV-2
and HIV and the dynamic effects of gel on the HIV and
HSV-2 epidemic. Walensky et al. [50] included only the
first generation of HIV infections averted. Numerous
programme implementation components were also in-
cluded in our analysis, such as training, mass media and
facility distribution costs, to provide a more compre-
hensive approach to costs than comparable studies to
date. However, we did not account for potential toxicity
or ART resistance as in Walensky et al. [50], because
the concerns in this area are limited, as the authors
themselves acknowledge. Moreover, the scenarios that
we have modelled are less optimistic than those consid-
ered previously [49]. This study makes lower assump-
tions regarding the likely coverage that can be achieved,
more optimistic assumptions about the impact of ART
on life expectancy and the discounting of future DALYs
averted (an sometime omitted step [51]. Consequently,
we produce a far more conservative estimate of impact
and cost-effectiveness.
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Our modelling stresses the importance of maintaining
condom use following microbicide introduction, to avoid
large reductions in impact and cost-effectiveness. This
issue is particularly of concern if condom use is already
high [48], and for a microbicide with lower efficacy, as
concomitant reductions in condom use could even lead
to increases in the overall number of infections [48].
Similarly, our analyses highlight the degree to which the
costs of gel introduction will be affected by programme
costs, including the unit cost of gels, and the required
frequency of HIV testing. For this reason, further research
is needed to identify the optimal spacing between HIV
testing, with the aim of achieving an appropriate balance
between what may be required to minimise the potential
for resistance and be feasible for women and health
systems. Similarly, research to explore whether a single
dose of tenofovir-containing gel, applied prior to sex,
could be effective at reducing a woman’s risk of acquiring
HIV is needed [52], to help reduce the product costs, as
well as make gel use less burdensome for women.
The fact that 17% of VOICE participants reported
engaging in anal intercourse during the 3-month period
prior to enrolment highlights an important area for fu-
ture modelling work [9]. For such modelling, data is
needed from different sites and population groups on
the frequency of anal sex over a specific timeframe (e.g.
past 3 or 6 months), and whether a condom and/or gel
is used during the last anal sex-act.
Although it is tempting to draw broader, national or
regional conclusions from this analysis, our model pro-
jections may not be generalisable to other settings with
different epidemic and behavioural profiles and different
price levels. However, the impact we predict compares
favourably with previous modelling of a hypothetical mi-
crobicide introduced into an area within Gauteng [19],
and with modelling studies of the impact of male circum-
cision on HIV incidence in various settings of sub-Saharan
Africa [53-55], matched to the same intervention assump-
tions made here [56].
The results are also highly sensitive to the discount rate
used. Our central estimate used a 3% discount rate as
commonly applied in international studies. However, when
using the upper bound of 6%, just above the South African
national discount rate of 5.5%, the cost-effectiveness of
microbicides would worsen dramatically by 77%. Although
not a realistic price to expect during mass-production, the
programme’s incremental cost-effectiveness, at the current
product cost of $1.60 per dose would still be highly
cost-effective at $2,825 per DALY averted even using a
6% discount rate.
Some have questioned the viability of tenofovir gel
given recent disappointing evidence of low user adher-
ence in the VOICE trial. That users have a difficult time
with adherence, however, should come as no surprise.
Inconsistent adherence is the norm for both medications
and any prevention methods that are user-controlled.
Nonetheless, every indication is that the South African
government and international donors are prepared to seek
licensure for tenofovir gel should the results of the
CAPRISA trial be sustained in the on-going FACTS 001
trial. Given that policymakers will soon face a key decision
point regarding the possible introduction and scale up of
tenofovir gel, the findings of this article are highly relevant.
Despite intuitions to the contrary, it appears from the
results of VOICE, FEMPREP, and other trials of daily oral
or vaginal prophylaxis, that women seem better able to
adhere to the coitally-dependent BAT-24 regimen than
daily use.
Moreover, even if the attention of the wider field has
shifted towards long-acting modalities such as the vaginal
ring and injection, these products are still many years
from licensure and there is undoubtedly benefit of
beginning to prepare consumers for using ARVs to
prevent infection. There will always be a market for
methods like the vaginal gel that will likely not require
on-going HIV testing and that can be positioned as a sex-
ual lubricant with additional HIV fighting powers. Though
highly cost-effective prevention options are available for
men (VMMC and male condoms), there is still a great
need to seek coitally-dependent options that women can
initiate, such as microbicides, in whichever formulation.
This study has used epidemiological and cost modelling
to estimate the impact of microbicide introduction among
women of the general population in the Gauteng Province
in South Africa. We used highly conservative assumptions
to estimate gel impact and found that microbicides have
the potential to significantly reduce HIV incidence among
women in Gauteng. This is the most comprehensive
model of the costs of microbicide introduction available
in the literature to date and, even under the very conserva-
tive assumptions this analysis, estimated that microbicide
introduction is very likely to be highly cost-effective.
However this analysis also highlighted the importance
of continued strong condom distribution and counsel-
ling programmes to maintain condom use and the need
for identifying innovative approaches for supporting
microbicide adherence.
Endnotes
aAdherence estimates based on applicator returns for
the remaining 884 women indicate that, on average, 72.2%
(median = 60.2%) of self-reported sex-acts in the last 30
days were covered by two doses of gel.
bIt should be noted that condom use outside the trial
setting is lower and our approach will therefore underesti-
mate the impact of microbicides on HIV incidence.
cThe 6% discount rate is consistent with the South
African central bank discount rate of 5.5% [57].
Terris-Prestholt et al. BMC Infectious Diseases 2014, 14:14 Page 9 of 11
http://www.biomedcentral.com/1471-2334/14/14
Additional file
Additional file 1: Table S1. Average additional life expectancy and
reduction in transmission probabilities for the population attributable to
ART treatment. Table S2. Behavioural and demographic parameters used
in the model for Gauteng Province. Table S3. Biological parameters used
in the model for Gauteng Province. Table S4. Data used in model fitting:
Prevalence of Sexually Transmitted Infections – Gauteng/South Africa.
Table S5. Cost inputs, assumptions and sources.
Abbreviations
ART: Antiretroviral therapy; CI: Confidence interval for data estimates;
Crl: Credibility interval for model projections – defined as the 2.5 to 97.5%
percentile range; DALY: Disability adjusted life year; DfID: Department for
International Development; FSW: Female sex workers; HIV: Human
immunodeficiency virus; HSV-2: Herpes simplex type 2; ICER: Incremental
cost-effectiveness ratio; IPM: International Partnership for Microbicides;
MDP: Microbicide development programme.
Competing interests
I have read the journal’s policy and have the following conflicts: AF, FTP, AC,
PV, CW received a grant from IPM in the initial development of these
models. At the time, TM was employed by IPM. IPM aims to promote the
development and delivery of safe and effective microbicides around the
globe. LH was previously the director for the Global Campaign for
Microbicides.
Authors’ contributions
Conceptualised the study: AF, PV, FTP, TM, AC, LH,CW; Developed the model:
PV and AF; Undertook the impact modelling: AC and AF and PV; Undertook
the cost modelling: FTP; Wrote the first draft of the manuscript: AF, FTP;
Contributed to the writing of the manuscript: LH, AC, GMR, SDM, TM, HR, PV,
CW; Criteria for authorship read and met: AF, FTP, AC, LH, GMR, SDM, TM, HR,
PV, CW. Agree with manuscript results and conclusions AF, FTP, AC, LH, GMR,
SDM, TM, HR, PV, CW. All authors read and approved the final manuscript.
Acknowledgements
The authors are grateful for the ongoing support, advice and input from
Céline Mias, Saul Walker, Youssef Tawfik and Vimala Raghavendran. We thank
David Friend for contributing likely tenofovir gel product costs under various
production scales. The authors are extremely grateful to Christine Michaels,
Chiweni Chimbwete, Emeka Okonji, Richard Hayes, Mitzy Gafos, Lilani
Kumaranayake, Jocelyn Moyes, Mags Beksinska, Sibongile Walaza, Claire von
Mollendorf, Jennifer Smit, Anna Vassall and Michelle Remme for their support
and input into this work, and to Salim S. Abdool Karim and Brian Williams for
sharing trial data on condom and gel use and. The authors are also indebted
to all the participants of the various microbicide trials.
Funding
The Bill & Melinda Gates Foundation provided grant support for some of the
activities described in this paper. This research project was conducted in
conjunction with the International Partnership for Microbicides (IPM), funded
by the European Union, and contributes to the Microbicides Development
Programme (MDP). MDP is a partnership of African and European academic/
government institutions and commercial organisations. MDP is funded by
the British Government Department for International Development (DfID)
and the UK Medical Research Council. AF, FTP, AC, PV, GMR and CW were
also members of the DfID Research Programme Consortium for Research
and Capacity Building in Sexual and Reproductive Health and HIV in
Developing Countries of the LSHTM.
Author details
1London School of Hygiene & Tropical Medicine, London, UK. 2Health
Economics and Epidemiology Research Office, Department of Medicine,
Faculty of Health Sciences, University of the Witwatersrand, Johannesburg,
South Africa. 3Center for Global Health and Development, Boston University,
Boston, USA. 4Wits Reproductive Health and HIV Research Institute,
Johannesburg, South Africa. 5International Partnership for Microbicides, Silver
Spring, MD, USA.
Received: 21 March 2013 Accepted: 24 December 2013
Published: 9 January 2014
References
1. Cohen M, Chen Y, McCauley M, Gamble T, Hosseinipour M, Kumarasamy N,
et al: Prevention of HIV-1 infection with early antiretroviral therapy.
N Engl J Med 2011, 365:493–505.
2. Grant R, Lama J, Anderson P, McMahan V, Liu A, Vargas L, et al:
Preexposure chemoprophylaxis for HIV prevention in men who have sex
with men. N Engl J Med 2010, 363:2587–2599.
3. Baeten J, Donnell D, Ndase P, et al: Antiretroviral prophylaxis for HIV
prevention in heterosexual men and women. N Engl J Med 2012, 367:399–410.
4. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM,
Henderson FL, Pathak SR, Soud FA, Chillag KL, et al: Antiretroviral
Preexposure Prophylaxis for Heterosexual HIV Transmission in Botswana.
N Engl J Med 2012, 367:423–434.
5. Karim QA, Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, Kharsany
AB, Sibeko S, Mlisana KP, Omar Z, et al: Effectiveness and Safety of
Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV
Infection in Women. Science 2010. Epub:http://www.sciencemag.org/
content/early/2010/07/19/science.1193748?explicitversion=true.
6. Karim SSA: Results of the CAPRISA 004 trial of tenofovir gel. In XVIII
International AIDS Conference 18–23 July. Vienna, Austria; 2010.
7. Cates W Jr: After CAPRISA 004: time to re-evaluate the HIV lexicon.
Lancet 2010, 376:495–496.
8. FACTS 001 Study. http://www.facts-consortium.co.za/?page_id=83.
9. Marrazzo J, Ramjee G, Nair G, Palanee T, Mkhize B, Nakabiito C, Taljaard M, Piper J,
Gomez-Feliciano K, Chirenje M, VOICE Study Team: Pre-exposure Prophylaxis
for HIV in Women: Daily Oral Tenofovir, Oral Tenofovir/Emtricitabine, or
Vaginal Tenofovir Gel in the VOICE Study (MTN 003). In 20th Conference on
Retroviruses and Opportunistic Infections; March 3–6. Atlanta, Georgia, USA; 2013.
10. Bärnighausen T, Bloom DE, Humair S: Economics of antiretroviral
treatment vs. circumcision for HIV prevention. Proc Natl Acad Sci U S A
2012, 109:21271–21276.
11. Shisana O, Rehle T, Simbayi L, Zuma K, Jooste S, Pillay-van-Wyk V, Mbelle N,
Van Zyl J, Parker W, Zungu N, et al: South African national HIV prevalence,
incidence, behaviour and communication survey. A turning tide among
teenagers?. Cape Town: HSRC Press; 2009.
12. Shisana O, Rehle T, Simbayi L, Parker W, Zuma K, Bhana A, Connolly C,
Jooste S, Pillay V: South African National HIV Prevalence. Behaviour and
Communication Survey: HIV Incidence; 2005.
13. Dunkle K, Beksinka M, Rees H, Ballard R, Htun Y, Wilson ML: Risk factors for
HIV infection among sex workers in Johannesburg, South Africa.
Int J STD AIDS 2005, 16:256–261.
14. RHRU: Reproductive Health Research Unit Behavioural Sentinel Survey Data
Report - Clients of family planning - Gauteng. Johannesburg, South Africa:
Reproductive Health Research Unit, University of the Witwatersrand; 2000.
15. Watts C, Foss A, Kumaranayake L, Cox A, Terris-Prestholt F, Vickerman P:
Identifying optimal strategies for microbicide distribution in India and
South Africa: Modelling and cost-effectiveness analyses. In International
Partnership for Microbicides with the London School of Hygiene and Tropical
Medicine. Brussels and London; 2008.
16. Rees H: Service Delivery and Demand Challenges in Introducing new health
products. Mexico City: Microbicide Access Forum; 2008.
17. Department of Health Medical Research Council, OrcMacro: South Africa
Demographic and Health Survey 2003. Pretoria: Department of Health
Republic of South Africa; 2007.
18. Heise L, Watts C, Foss A, Vickerman P, Trussell J, Hayes R, McCormack S:
Apples and oranges? Interpreting success in HIV prevention trials.
Contraception 2011, 83:10–15.
19. Vickerman P, Foss A, Watts C: Using modeling to explore the degree to
which a microbicide's sexually transmitted infection efficacy may
contribute to the HIV effectiveness measured in phase 3 microbicide
trials. J Acquir Immune Defic Syndr 2008, 48:460–467.
20. Vickerman P, Watts C, Delany S, Alary M, Rees H, Heise L: The importance
of context: model projections on how microbicide impact could be
affected by the underlying epidemiologic and behavioral situation in 2
African settings. Sex Transm Dis 2006, 33:397–405.
21. Vickerman P, Foss AM, Pickles M, Deering K, Verma S, Demers E, Moses S,
Alary M, Boily M-C: Is the Indian HIV epidemic driven by commercial sex?
A modelling analysis from south India. AIDS 2010, 24:2563–2572.
Terris-Prestholt et al. BMC Infectious Diseases 2014, 14:14 Page 10 of 11
http://www.biomedcentral.com/1471-2334/14/14
22. Garnett GP, Anderson RM: Strategies for limiting the spread of HIV in
developing countries: conclusions based on studies of the transmission
dynamics of the virus. J Acquir Immune Defic Syndr Hum Retrovirol 1995,
9:500–513.
23. Weinstein MC, Graham JD, Siegel JE, Fineberg HV: Cost-effectiveness
analysis of AIDS prevention programs: concepts, complications and
illustrations. In Confronting AIDS. Edited by Turner CF, Miller HG, Moses LE.
Washington DC: National Academy Press; 1989:471–499.
24. Foss AM, Vickerman PT, Mayaud P, Weiss H, Ramesh BM, Reza-Paul S,
Washington R, Blanchard J, Moses S, Lowndes CM, et al: Modelling the
interactions between HSV-2 and HIV: implications for the HIV epidemic
in southern India. Sex Transm Infect 2011, 87:22–27.
25. Wawer MJ, Gray RH, Sewankambo NK, Serwadda D, Li X, Laeyendecker O,
Kiwanuka N, Kigozi G, Kiddugavu M, Lutalo T, et al: Rates of HIV-1
transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda.
J Infect Dis 2005, 191:1403–1409.
26. Shisana O, Simbayi L: Nelson Mandela/HSRC study of HIV/AIDS. South African
National HIV Prevalence, Behavioural Risks and Mass Media. The Human
Sciences Research Council: Cape Town; 2002.
27. Johnson LF, Coetzee DJ, Dorrington RE: Sentinel surveillance of sexually
transmitted infections in South Africa: a review. Sex Transm Infect 2005,
81:287–293.
28. CHOosing Interventions that are Cost Effective (WHO-CHOICE).
[http://www.who.int/choice/costs/CER_thresholds/en/]
29. Bassett IV, Giddy J, Nkera J, Wang B, Losina E, Lu Z, Freedberg KA, Walensky
RP: Routine voluntary HIV testing in Durban, South Africa: the experience
from an outpatient department. J Acquir Immune Defic Syndr 2007,
46:181–186.
30. Terris-Prestholt F, Kumaranayake L, Obasi AI, Cleophas-Mazige B, Makokha
M, Todd J, Ross DA, Hayes RJ: From Trial Intervention to Scale-Up: Costs
of An Adolescent Sexual Health Program in Mwanza, Tanzania.
Sex Transm Dis 2006, 33:S133–139.
31. Terris-Prestholt F, Michaels C, Kumaranayake L, Meyer-Rath G, Watts C:
Costing Microbicide Distribution: Estimating cost-effectiveness & modelling
potential role out. Entebbe, Uganda: MDP301 Annual Investigators Meeting;
2009.
32. Meyer-Rath G: Public Sector Salary Costs. ; 2009. Personal
Communicatuion.
33. Cleary S, Bouille A, McIntyre D, et al: Cost-effectiveness of Antiretroviral
Treatment for HIV-positive Adults in a South African Township. Cape Town:
University of Cape Town, Health Systems Trust, Medecins Sans Frontieres;
2004.
34. Gilson L, Mkanje R, Grosskurth H, Mosha F, Picard J, Gavyole A, Todd J,
Mayaud P, Swai R, Fransen L, et al: Cost-effectiveness of improved
treatment services for sexually transmitted diseases in preventing HIV-1
infection in Mwanza Region, Tanzania. Lancet 1997, 350:1805–1809.
35. Bollinger L, Stover J, Boulle A, Cleary S: Database of Unit Costs for HIV and
AIDS interventions in South Africa: Resource Needs for HIV/AIDS: Model
for estimating resources needed for prevention, care and mitigation. In
Book Database of Unit Costs for HIV and AIDS interventions in South Africa:
Resource Needs for HIV/AIDS: Model for estimating resources needed for
prevention, care and mitigation. City: Centre for Economic Governance and
AIDS in Africa; 2006.
36. Friend D: Tenofovir 1% gel, Current Prices and Expected Prices at
Different Scales. 2012. Personal communication.
37. Johnson L: Access to antiretroviral treatment in South Africa, 2004–2011.
S Afr J HIV Med 2012, march:22–27.
38. Meyer-Rath G: National ART Cost Model, South Africa. Johannesburg: Health
Economics and Epidemiology Research Office, Boston University/University
of the Witwatersrand; 2011.
39. Johansson KA, Robberstad B, Norheim OF: Further Benefits by Early Start
of HIV Treatment in Low Income Countries: Survival Estimates of Early
Versus Deferred Antiretroviral Therapy. AIDS Res Ther 2010, 7:3.
doi:10.1186/1742-6405-7-3.
40. Fox-Rushby JA, Hanson K: Calculating and presenting disability adjusted
life years (DALYs) in cost-effectiveness analysis. Health Policy Plan 2001,
16:326–331.
41. Ortblad KF, Lozano R, Murray CJ: The burden of HIV: insights from the
GBD 2010. AIDS (London, England) 2013.
42. GDP per capits (current US$). http://data.worldbank.org/indicator/NY.GDP.
PCAP.CD.
43. Kashuba AD, Abdool Karim SS, Kraft E, White N, Sibeko S, Werner L, Mansoor
LE, Gengiah T, Sidhoo S, Abdool Karim Q: Do systemic and genital tract
tenofovir concentrations predict HIV seroconversion in the CAPRISA 004
tenofovir gel trial? In XVIII International AIDS Conference 18–23 July. Vienna,
Austria; 2010.
44. Watts CH, Kumaranayake L, Vickerman P, Terris-Prestholt F: The public health
impact of microbicides: model projections. Report from the Public Health
Benefits Working Group. In The Rockefeller Foundation Microbicide Initiative.
2002. http://www.global-campaign.org/clientfiles/rep7_publichealth.pdf.
45. Watts C, Vickerman P: The impact of microbicides on HIV and STD
transmission: model projections. AIDS 2000, 15:S43–S44.
46. Vickerman P, Devine A, Foss AM, Delany-Moretlwe S, Mayaud P, Meyer-Rath G:
The cost-effectiveness of herpes simplex virus-2 suppressive therapy
with daily aciclovir for delaying HIV disease progression among
HIV-1-infected women in South Africa. Sex Transm Dis 2011, 38:401–409.
47. Terris-Prestholt F, Kumaranayake L, MacPhail C, Rees H, Watts C:
Determinants of South African Women’s Demand for New Barrier
Methods and their Distribution: Analysis of a Discrete Choice
Experiment. In IAEN; 1–2 August; Cuernavaca; 2008.
48. Foss AM, Vickerman PT, Heise L, Watts CH: Shifts in condom use following
microbicide introduction: should we be concerned? AIDS 2003,
17:1227–1237.
49. Williams BG, Karim SSA, Karim QA, Gouws E: Epidemiological impact of
tenofovir gel on the HIV epidemic in South Africa. J Acquir Immune Defic
Syndr 2011, 58:207–210.
50. Walensky RP, Park JE, Wood R, Freedberg KA, Scott CA, Bekker LG, Losina E,
Mayer KH, Seage GR 3rd, Paltiel AD: The cost-effectiveness of
pre-exposure prophylaxis for HIV infection in South African women.
Clin Infect Dis 2012, 54:1504–1513.
51. Verguet S, Walsh JA: Vaginal microbicides save money: a model of
cost-effectiveness in South Africa and the USA. Sex Transm Infect 2010,
86:212–216.
52. MDP Statement on the Discontinuation of Tenofovir gel in the VOICE Trial.
http://www.mdp.mrc.ac.uk/.
53. Gray RH, Li X, Kigozi G, Serwadda D, Nalugoda F, Watya S, Reynolds SJ,
Wawer M: The impact of male circumcision on HIV incidence and cost
per infection prevented: a stochastic simulation model from Rakai,
Uganda. AIDS 2007, 21:845–850.
54. Hallett TB, Singh K, Smith JA, White RG, Abu-Raddad LJ, Garnett GP:
Understanding the impact of male circumcision interventions on the
spread of HIV in southern Africa. PLoS One 2008, 3:e2212.
55. White RG, Glynn JR, Orroth KK, Freeman EE, Bakker R, Weiss HA,
Kumaranayake L, Habbema JD, Buve A, Hayes RJ: Male circumcision for HIV
prevention in sub-Saharan Africa: who, what and when? AIDS 2008,
22:1841–1850.
56. Cox AP, Foss AM, Vickerman PT, Chimbwete C, Okonji E, Terris-Prestholt F,
Beksinska M, Walaza S, von Mollendorf C, Smit J, et al: Making realistic
impact projections for new HIV prevention technologies: looking beyond
a product’s efficacy. In 18th International Society for Sexually Transmitted
Diseases Research; 28 June - 1 July. London, UK; 2009.
57. Central Bank Rates. www.cbrates.com.
doi:10.1186/1471-2334-14-14
Cite this article as: Terris-Prestholt et al.: Cost-effectiveness of tenofovir
gel in urban South Africa: model projections of HIV impact and
threshold product prices. BMC Infectious Diseases 2014 14:14.
Terris-Prestholt et al. BMC Infectious Diseases 2014, 14:14 Page 11 of 11
http://www.biomedcentral.com/1471-2334/14/14
